Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Serbia

Marie Skłodowska-Curie Action · Running

INNOVATOC Innovative exploitation of PVAT-vascular crosstalk through integrated tissue biology, animal models, and organ-on-chip to deliver clinically validated ASCVD biomarkers

Coordinator
Farmaceutski Fakultet Univerziteta U Beogradu, Serbia
Runs
1 January 2027 to 31 December 2030
Status
Running
EU funding
€1.3m
Total cost
—
Partners
13 organisations in 6 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101344679

What the project is doing

In the project's own words, from its summary on CORDIS.

Cardiovascular disease (CVD) remains the leading cause of mortality in Europe, driven by unresolved vascular inflammation and the lack of mechanistically grounded biomarkers. INNOVATOC addresses this challenge by investigating perivascular adipose tissue (PVAT) as a key regulator of vascular inflammation and plaque instability through a structured programme of international, intersectoral and interdisciplinary knowledge exchange.

The project will generate a unique cross-species PVAT–plaque multi-omics dataset from human tissues and complementary animal models. Integrated analysis, supported by single-nuclei RNA sequencing, will enable identification and prioritization of mediators involved in PVAT–vascular crosstalk and inflammation resolution, followed by functional validation in advanced adipocyte–vascular–immune interaction systems. INNOVATOC will deliver: 1) prioritised panel of 15 candidate biomarkers (miRNA, protein and specialised pro-resolving lipid mediators, SPLM), 2) validated LC–MS/MS-based assay for targeted SPLM quantification, designed for scalability and clinical applicability, 3) novel organ-on-chip (OoC) prototype that recapitulates PVAT–vascular interactions under physiologically controlled conditions.

These outputs will support the establishment of a predictive biomarker panel for cardiovascular risk prediction, validated in well-characterised clinical cohorts. Through structured secondments and joint activities, INNOVATOC will enable intensive knowledge transfer across disciplines and sectors, fostering innovation in biomarker discovery, analytical technologies, and organ-on-chip systems. The consortium brings together 6 academic institutions, 5 non-academic partners (including 2 SMEs and 3 clinical centres), and 1 international associated partner, ensuring balanced expertise across research, clinical translation, and technological development, and supporting sustainable long-term collaboration networks.

Topics

Who is involved

OrganisationCityCountryRole
Farmaceutski Fakultet Univerziteta U BeograduBelgradeSerbiaCoordinator
Royal Institution for the Advancement of Learning Mcgill UniversityMontrealCanadaAssociatedpartner
Asklipios Idiotiko Polyiatreio Iatriki Anonymi EtaireiaHeraklionGreeceParticipant
Idryma Technologias Kai ErevnasIrakleioGreeceParticipant
Panepistimio KritisRethimnoGreeceParticipant
Biosfer Teslab SLReusSpainParticipant
B.s.n. Biological Sales Networks.r.l.CastelleoneItalyParticipant
Multimedica SpAMilanoItalyParticipant
Universita Degli Studi Di MilanoMilanoItalyParticipant
Istrazivacko-Razvojni Institut Za Vestacku Inteligenciju SrbijeNovi SadSerbiaParticipant
Klinicko-Bolnicki Centar Dr Dragisa Misovic-DedinjeBeogradSerbiaParticipant
Queen Mary University of LondonLondonUnited KingdomParticipant
The University of EdinburghEdinburghUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI